Status:
UNKNOWN
A Clinical Study to Evaluate the Safety and Efficacy of Mesenchymal Stem Cells in Liver Cirrhosis
Lead Sponsor:
Chaitanya Hospital, Pune
Conditions:
Liver Cirrhosis
Eligibility:
All Genders
25-65 years
Phase:
PHASE1
PHASE2
Brief Summary
Cirrhosis is caused by sustained liver damage over several years either by alcohol, viral infection (Hepatitis B, C), a toxic substance (for eg. drugs, excess copper or iron in the liver), or by block...
Detailed Description
In this study, the patients with liver cirrhosis will undergo administration of human Mesenchymal stem cell MSCs intravenously for these patients.To observe the results Liver function will be monitore...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- 25 -65 Ages Eligible for Study
- Clinical diagnosis of liver cirrhosis
- Ability to comprehend the explained protocol and thereafter give an informed consent as well as sign the required Informed Consent Form (ICF) for the study.
- Expecting lifetime is over three years
- Ready to come all visits
- Exclusion Criteria:
- History of life threatening allergic or immune-mediated reaction
- Positive test results for HIV and AIDS complex ,HCV , HbsAg and Syphilis
- Malignancies
- Sepsis
- Vital organs failure
- Pregnant or lactating women
- Subject who has been transplanted recently
- If the investigator or treating physician feels that the Subject with any disease or condition would interfere with the trial or the safety of patient
Exclusion
Key Trial Info
Start Date :
December 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2014
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01877759
Start Date
December 1 2013
End Date
December 1 2014
Last Update
October 9 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chaitanya Hospital
Pune, Maharashtra, India, 411009